{"id":16864,"date":"2024-12-05T14:43:20","date_gmt":"2024-12-05T06:43:20","guid":{"rendered":"https:\/\/flcube.com\/?p=16864"},"modified":"2024-12-05T14:43:23","modified_gmt":"2024-12-05T06:43:23","slug":"wuhan-kaideweisi-biotechnology-secures-series-b-funding-for-gynecologic-oncology-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=16864","title":{"rendered":"Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion"},"content":{"rendered":"\n<p>Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised close to RMB 200 million (USD 27.5 million) via a Series B financing round. The round was led by Fir Health Capital with a contribution of RMB 50 million (USD 6.9 million), and was also supported by Wuhan Hi-Tech Holding, Hongtai Group, Hubei Science Technology Investment, and Chuchuang Investment Group. The funds raised will be allocated towards the clinical development and market expansion of the company&#8217;s products within the gynecologic oncology diagnosis and treatment sector.<\/p>\n\n\n\n<p><strong>In-House IVD Kits and Their Impact on Gynecologic Cancer Diagnosis<\/strong><br>Kaideweisi Bio boasts two in-house developed in vitro diagnostic (IVD) kits that have been granted fast-track statuses in China. These kits are expected to significantly enhance the rapid screening and precision diagnosis and treatment of gynecological tumors, including endometrial cancer and cervical cancer, as well as their precancerous lesions. The availability of such diagnostic tools is crucial for improving patient outcomes in the field of gynecologic oncology.<\/p>\n\n\n\n<p><strong>Oncolytics and HPV Therapeutic Vaccine Development<\/strong><br>In addition to its diagnostic offerings, Kaideweisi Bio is actively developing an oncolytic virus product and an HPV therapeutic vaccine. The oncolytic virus product has received clearance for a Phase I study, marking a significant step forward in the company&#8217;s efforts to contribute to the treatment of gynecologic cancers.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised&#8230;<\/p>\n","protected":false},"author":1,"featured_media":16866,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,20,2624],"class_list":["post-16864","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-finance","tag-kaideweisi-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised close to RMB 200 million (USD 27.5 million) via a Series B financing round. The round was led by Fir Health Capital with a contribution of RMB 50 million (USD 6.9 million), and was also supported by Wuhan Hi-Tech Holding, Hongtai Group, Hubei Science Technology Investment, and Chuchuang Investment Group. The funds raised will be allocated towards the clinical development and market expansion of the company&#039;s products within the gynecologic oncology diagnosis and treatment sector.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=16864\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion\" \/>\n<meta property=\"og:description\" content=\"Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised close to RMB 200 million (USD 27.5 million) via a Series B financing round. The round was led by Fir Health Capital with a contribution of RMB 50 million (USD 6.9 million), and was also supported by Wuhan Hi-Tech Holding, Hongtai Group, Hubei Science Technology Investment, and Chuchuang Investment Group. The funds raised will be allocated towards the clinical development and market expansion of the company&#039;s products within the gynecologic oncology diagnosis and treatment sector.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=16864\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-05T06:43:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-05T06:43:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"450\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16864#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16864\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion\",\"datePublished\":\"2024-12-05T06:43:20+00:00\",\"dateModified\":\"2024-12-05T06:43:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16864\"},\"wordCount\":235,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16864#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0512-1.png\",\"keywords\":[\"Biotech\",\"Finance\",\"Kaideweisi Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16864#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16864\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=16864\",\"name\":\"Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16864#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16864#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0512-1.png\",\"datePublished\":\"2024-12-05T06:43:20+00:00\",\"dateModified\":\"2024-12-05T06:43:23+00:00\",\"description\":\"Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised close to RMB 200 million (USD 27.5 million) via a Series B financing round. The round was led by Fir Health Capital with a contribution of RMB 50 million (USD 6.9 million), and was also supported by Wuhan Hi-Tech Holding, Hongtai Group, Hubei Science Technology Investment, and Chuchuang Investment Group. The funds raised will be allocated towards the clinical development and market expansion of the company's products within the gynecologic oncology diagnosis and treatment sector.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16864#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16864\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16864#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0512-1.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/0512-1.png\",\"width\":1080,\"height\":450,\"caption\":\"Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16864#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised close to RMB 200 million (USD 27.5 million) via a Series B financing round. The round was led by Fir Health Capital with a contribution of RMB 50 million (USD 6.9 million), and was also supported by Wuhan Hi-Tech Holding, Hongtai Group, Hubei Science Technology Investment, and Chuchuang Investment Group. The funds raised will be allocated towards the clinical development and market expansion of the company's products within the gynecologic oncology diagnosis and treatment sector.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=16864","og_locale":"en_US","og_type":"article","og_title":"Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion","og_description":"Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised close to RMB 200 million (USD 27.5 million) via a Series B financing round. The round was led by Fir Health Capital with a contribution of RMB 50 million (USD 6.9 million), and was also supported by Wuhan Hi-Tech Holding, Hongtai Group, Hubei Science Technology Investment, and Chuchuang Investment Group. The funds raised will be allocated towards the clinical development and market expansion of the company's products within the gynecologic oncology diagnosis and treatment sector.","og_url":"https:\/\/flcube.com\/?p=16864","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-05T06:43:20+00:00","article_modified_time":"2024-12-05T06:43:23+00:00","og_image":[{"width":1080,"height":450,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512-1.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=16864#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=16864"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion","datePublished":"2024-12-05T06:43:20+00:00","dateModified":"2024-12-05T06:43:23+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=16864"},"wordCount":235,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=16864#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512-1.png","keywords":["Biotech","Finance","Kaideweisi Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=16864#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=16864","url":"https:\/\/flcube.com\/?p=16864","name":"Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=16864#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=16864#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512-1.png","datePublished":"2024-12-05T06:43:20+00:00","dateModified":"2024-12-05T06:43:23+00:00","description":"Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised close to RMB 200 million (USD 27.5 million) via a Series B financing round. The round was led by Fir Health Capital with a contribution of RMB 50 million (USD 6.9 million), and was also supported by Wuhan Hi-Tech Holding, Hongtai Group, Hubei Science Technology Investment, and Chuchuang Investment Group. The funds raised will be allocated towards the clinical development and market expansion of the company's products within the gynecologic oncology diagnosis and treatment sector.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=16864#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=16864"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=16864#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512-1.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512-1.png","width":1080,"height":450,"caption":"Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=16864#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Wuhan Kaideweisi Biotechnology Secures Series B Funding for Gynecologic Oncology Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/0512-1.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16864"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16864\/revisions"}],"predecessor-version":[{"id":16867,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16864\/revisions\/16867"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/16866"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}